Wedbush Predicts Increased Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Wedbush lifted their Q2 2025 EPS estimates for Denali Therapeutics in a note issued to investors on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.76) per share for the quarter, up from their prior estimate of ($0.77). Wedbush has a “Outperform” rating and a $30.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Denali Therapeutics’ FY2025 earnings at ($3.17) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.77) EPS and FY2028 earnings at ($1.10) EPS.

Several other equities analysts have also issued reports on the company. The Goldman Sachs Group lowered their price target on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $31.00 price target on the stock. Oppenheimer cut their target price on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. William Blair upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, B. Riley reaffirmed a “buy” rating and set a $35.00 price target (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.79.

Denali Therapeutics Price Performance

DNLI opened at $14.26 on Monday. The stock has a 50-day moving average price of $14.20 and a 200-day moving average price of $19.87. The firm has a market cap of $2.07 billion, a PE ratio of -5.17 and a beta of 1.49. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same quarter last year, the firm posted ($0.68) earnings per share.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aberdeen Group plc increased its stake in shares of Denali Therapeutics by 88.9% in the first quarter. Aberdeen Group plc now owns 759,815 shares of the company’s stock worth $10,330,000 after purchasing an additional 357,533 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in shares of Denali Therapeutics by 20.7% during the 1st quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company’s stock valued at $164,000 after buying an additional 2,072 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after buying an additional 1,551 shares during the period. Nuveen LLC purchased a new stake in Denali Therapeutics in the 1st quarter worth $4,390,000. Finally, Entropy Technologies LP bought a new stake in Denali Therapeutics during the first quarter valued at about $152,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.